Special Issue

Personalized Diagnosis and Treatment of Urological Diseases

Message from the Guest Editors

History: With the advent of molecular diagnostics and novel drug delivery systems, personalized therapy has revolutionized the management of conditions such as prostate cancer, benign prostatic hyperplasia (BPH), and recurrent urinary tract infections. Aim and Scope: This Special Issue aims to explore cutting-edge advancements in the personalized diagnosis and treatment of urological diseases. The focus will be on integrating clinical, genomic, and imaging data to develop tailored therapies and on how drug delivery systems can be optimized for individualized care. Cutting-edge Research: We are particularly interested in research that bridges the gap between novel diagnostic tools, such as AI-based imaging or biomarkers, and therapeutic interventions, including gene therapy, targeted drug delivery, and the application of 3D printing in urology. Papers of Interest: We welcome original research and comprehensive reviews that address personalized diagnostic techniques, innovative drug delivery systems, and therapeutic approaches in urology. Contributions that demonstrate translational applications and patient-centered outcomes are highly encouraged.

Guest Editors

Dr. Alexandru Ciudin

Urology Department, Hospital Universitari de Mollet, 08100 Barcelona, Spain

Dr. Lluís Peri

Urology Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain

Deadline for manuscript submissions

10 April 2026

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).